The impact of epigenetic chemical probes: expanding targeting modalities and disease understanding
Essays in Biochemistry · 18.11.2026
DOI: 10.1042/ebc20260009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Essays in Biochemistry, online erschienen am 18.11.2026. Verfasst von Philip Barbulescu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Structural Genomics Consortium, Toronto, ON, Canada. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR | Institute of Cancer Research (IC).
Abstract (Originalsprache)
Small-molecule chemical modulators (chemical probes) targeting epigenetic regulators are essential tools for research by enabling precise temporal control over chromatin dynamics. Over the past two decades, large international efforts have produced hundreds of validated and openly accessible chemical probes. While the field was initially driven by occupancy-based catalytic inhibitors, there has been a recent shift toward context-dependent target engagement and induced proximity strategies. By repurposing established chemical ligands, next-generation heterobifunctional modalities (e.g., PROTACs and RIPTACs) can drive targeted protein degradation or disrupt multi-protein complexes to achieve deeper functional effects. In the present review, we discuss the evolution of epigenetic chemical probes, the emergence of induced proximity strategies, and the importance of recognizing that different targeting modalities for a given protein may yield distinct biological outcomes. Collectively, the history of epigenetic probes provides a foundation for Target 2035, an international initiative led by the Structural Genomics Consortium aimed at developing pharmacological modulators across the human proteome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Structural Genomics Consortium, Toronto, ON, Canada.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
- Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Cheryl H Arrowsmith, Dalia Barsyte-Lovejoy
Förderung
- CIHR | Institute of Cancer Research (IC)
Zitieren
APA
Barbulescu, P., Arrowsmith, C. H., & Barsyte-Lovejoy, D. (2026). The impact of epigenetic chemical probes: expanding targeting modalities and disease understanding. Essays in Biochemistry. https://doi.org/10.1042/ebc20260009
Vancouver
Barbulescu P, Arrowsmith CH, Barsyte-Lovejoy D. The impact of epigenetic chemical probes: expanding targeting modalities and disease understanding. Essays in Biochemistry. 2026. doi:10.1042/ebc20260009
BibTeX
@article{Barbulescu2026,
author = {Barbulescu, Philip and Arrowsmith, Cheryl H and Barsyte-Lovejoy, Dalia},
title = {The impact of epigenetic chemical probes: expanding targeting modalities and disease understanding},
journal = {Essays in Biochemistry},
year = {2026},
doi = {10.1042/ebc20260009}
}
EUVIMED